Early Pregnancy Risk Metabolomic Diagnostics develops biomarker panels to assess risk of preeclampsia, gestational diabetes, preterm birth, and IUGR early in pregnancy, enabling personalized care. Opportunity: pilot lab-integrated testing with obstetric departments and clinical laboratories, focusing on workflow-friendly, validated assays and collaboration with maternal-fetal medicine specialists.

Lab Ready Assays The company translates biomarker panels into clinical laboratory assays, creating opportunities for licensing, contract development, or joint ventures with reference labs and hospital labs. Emphasize ISO 9001 quality management and regulatory readiness to ease adoption and scale manufacturing.

Strategic Partnerships Existing collaborations with SQU4RE.com, Renegade.bio, and the Preeclampsia Foundation demonstrate strong networks for validation, pilot populations, and co-funded projects. Leverage these relationships to expand outreach to academic medical centers, biotech ecosystems, and patient advocacy groups.

Funding Validation Funding rounds and award recognition provide credibility to pursue EU and national health grants, hospital pilots, and payer discussions. Use this traction to accelerate clinical validation, regulatory milestones, and market entry.

Geographic Growth Ireland-based with global potential; pursue expansion through lab partnerships and payer engagements in EU and US markets. Focus on high-value maternity care providers and scalable biomarker panels to drive broad adoption and revenue growth.